OHSONG PHARM passed the 2nd year's performance evaluation and submitted the 3rd year's plan for the Jeju Local Small Giant Company Promotion Project.

During the 1st year, OHSONG PHARM established a foundation for entering the Japanese pharmaceutical market directly.

During this period, OHSONG PHARM and its Japanese subsidiary, BRIO PHARMA, obtained a license to manufacture and sell in the Japanese medicine market.

Also, OHSONG PHARM conducted a gap analysis of the medical regulations between Japan and Korea.

In the 2nd year of the project, OHSONG PHARM developed a new item for entry into the Japanese market and signed a joint development agreement with Whan-In Pharmaceutical and Daewoong Pharmaceutical.

And, in the 3rd period, OHSONG PHARM will strive to launch new medicines in the Japanese market.

In particular, OHSONG PHARM was selected as a ‘2020, Small Giant Company of Korea’ thanks to the generous support of the Jeju-do local government’.